Drug intelligence / Profile preview

Retamol

Development stage
Unknown
Lead developer
Snig Pharmaceuticals
Modality
Small Molecules
Administration
Intravenous, Oral
01

Overview

Retamol is a branded generic formulation of paracetamol (acetaminophen) developed and marketed by SNIG Pharma. It is a small molecule non-opioid analgesic and antipyretic used for the management of mild to moderate pain and the reduction of fever. Retamol is particularly indicated for short-term treatment in clinical settings, such as post-operative care, where rapid relief is required or oral administration is not feasible. The drug's mechanism of action involves the inhibition of prostaglandin synthesis within the central nervous system and a direct effect on the hypothalamic heat-regulating center to produce antipyresis. It is commonly available as a 1000 mg intravenous infusion, providing a high-dose, fast-acting alternative to oral paracetamol formulations.

Brand names
Retamol
Other names
paracetamolacetaminophenN-acetyl-p-aminophenolAPAP
02

Targets

PTGS2 (Prostaglandin-Endoperoxide Synthase 2)PGHS-1 (Prostaglandin G/H Synthase 1)

Beyond the preview

Go deeper on Retamol.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Retamol.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call